Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLX-100
- Development stage
- Preclinical
- Lead developer
- ClexBio
- Modality
- Cell Therapies
- Administration
- Surgical Implantation
01
Overview
CLX-100 is a preclinical-stage tissue therapy developed by ClexBio for the treatment of acute and end-stage liver failure. Utilizing the proprietary VivoSet™ technology platform, CLX-100 consists of fully vascularized hepatic tissue engineered with microvascular networks to facilitate rapid engraftment and anastomosis with the host's vasculature. The therapy is entirely cell-synthesized, avoiding artificial materials, and combines three different cell types to create functional tissue structures that mimic human biology. It is designed to restore liver function, serving as either a bridge to transplant or a means to enable liver recovery.
- Other names
- fully vascularized hepatic tissue
Beyond the preview
Go deeper on CLX-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLX-100.